Pharmacogenomics · 2022 · 30 citations · 26 references
MedicineBioinformaticsOncologyCancer GeneticsChemotherapyMolecular OncologyCancer GenomicsCancer ProgressionCancer TranscriptomicsChemotherapy ResistanceNoncoding Rna In CancerTherapeutic ResistanceBreast Cancer ChemotherapyBreast Cancer Resistance MechanismsMicrorna Function In CancerMicrorna In CancerMicrorna Regulation In CancerMicrorna-mediated ResistanceTherapeutic Resistance MechanismsTreatment Response Biomarkers
Aim: To explore the roles of lncRNA MALAT1 and SHOC2 in breast cancer, and the potential connections to chemotherapy resistance in breast cancer. Materials & methods: Paclitaxel-resistant breast cancer cells were induced by gradually increasing intermittent doses. Bioinformatic analyses were performed to predict the regulated miRNAs of MALAT1. Results: High expressions of MALAT1 and SHOC2 contribute to paclitaxel resistance in breast cancer cells. MALAT1 sponges miR-497-5p enhance SHOC2 expression in paclitaxel-resistant breast cancer cells and contribute to paclitaxel resistance in breast cancer cells. Conclusion: Patients with high expression of MALAT1 and SHOC2 have a poorer response to paclitaxel. Upregulation of miR-497-5p could improve the treatment response to paclitaxel in patients with breast cancer by inhibiting MALAT1 and SHOC2.
26
New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)
E. Eisenhauer, P. Therasse, Jan Bogaerts et al. · European Journal of Cancer · 2008 · 29.5K citations
Cancer statistics for the year 2020: An overview
Jacques Ferlay, Murielle Colombet, Isabelle Soerjomataram et al. · International Journal of Cancer · 2021 · 5.7K citations · Full text
Ewan Birney, Shane Neph, Evelyn J. Cheung et al. · Nature · 2007 · 5.3K citations · Full text